AssetMark’s SOPHiA GENETICS SOPH Stock Holding History
Bought
Maintained
Sold
Other funds holding SOPH
AIC
ACM
AssetMark's SOPH Position: Q3 2026 in Review
AssetMark increased its SOPHiA GENETICS (SOPH) stake by 23% in Q3 2026, buying an estimated $14.8K and bringing the position to 10,897 shares worth $91.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1679.
AssetMark first reported a position in SOPH in Q1 2022 and has held it in 19 quarters since. 71 funds tracked by Wall St. Rank hold SOPH as of Q3 2026.
- AssetMark held 10,897 shares of SOPHiA GENETICS worth $91.3K as of Q3 2026.
- AssetMark bought 2,061 SOPHiA GENETICS shares in Q3 2026, an estimated $14.8K.
- SOPHiA GENETICS made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #1679 holding.
- AssetMark first reported a position in SOPHiA GENETICS in Q1 2022 and has held it in 19 quarters since.
- 71 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.